One of the main limitations of the SC route is the limited dosing volume which requires high concentration of mAb. However, advances in SC administration technologies have alleviated injection volume limitations. Higher volumes are now facilitated through the use of on-body SC delivery systems such as intradermal and patchable pumps for 5-10 ml injection volumes, and reports of novel technologies allowing volumes of 30 ml in self-administration SC routes are said to be feasible within the next decade (Datta-Mannan, 2019; Viola et al., 2018). The use of large volume wearable injector device (LVD) also aims at overcoming volume limitations of SC or IM injections allowing up to 10 ml with slower rates of bolus injection (Li & Easton, 2018).